Skip to main
PSTV
PSTV logo

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc exhibits a strong positive outlook due to its focused advancement in drug development, particularly with its lead candidate rhenium (186Re) obisbemeda, which has shown promising preliminary results in treating central nervous system cancers. The company is projected to experience a substantial increase in CNSiderelated revenues, expecting to reach approximately $1 million in 2025 and grow significantly to $38 million by 2032, driven by increasing adoption and state licensing. Additionally, the receipt of an $18 million grant from the Cancer Prevention and Research Institute of Texas positions Plus Therapeutics well to further its research and potential market reach in addressing leptomeningeal metastases.

Bears say

The analysis indicates a negative outlook for Plus Therapeutics Inc. primarily due to several risks associated with its product development. The potential failure of key candidates to prove safety and efficacy, coupled with uncertainties surrounding regulatory approvals and reimbursement, undermines investor confidence. Additionally, the dilution resulting from an equity raise has further impacted the valuation, leading to a downward adjustment of the price target from $3.00 to $2.00 per share.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.